Lawlor RT, et al. - Given that CD200 (a membrane protein, member of the type I immunoglobulin superfamily) has been recently indicated as a robust marker of well-differentiated neuroendocrine neoplasms, researchers assessed its role in differential diagnosis of solid pancreatic neoplasms. For this investigation, they immunostained for CD200 22 solid pseudopapillary neoplasms (SPNs), 8 acinar carcinomas (ACs), 2 pancreatoblastomas (PBs), 138 neuroendocrine tumors (PanNETs), and 48 ductal adenocarcinomas. According to the findings obtained, the vast majority of PanNETs (96%) displayed strong cytoplasmic and membranous staining for CD200. On the other hand, all pancreatic ductal adenocarcinomas (PDACs) were negative. It was noted that both PanNETs and SPNs express CD200. Results of this study suggested that CD200 has no role in the differential diagnosis among PanNET, SPN, or AC.